RxDoctor Payments Data

Nicole Batcheller

Family · Sioux City, IANPI 1861150385

Payments from drug & device makers

$794in general payments, 2019–2025

Across 37 payments — averaging $21.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$211
  • Merck$107
  • Novo Nordisk$91
  • Sanofi-aventis U.S. LLC$88
  • E.r. Squibb & Sons, L.L.C.$58
  • Pfizer$43
  • plus $196 from 9 others

What the payments were for

  • Food & beverage$794100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$794 in reported general payments places this provider in the 75th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$59,899
Medicare patients
558
Services billed
788

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban404$267,272
XareltoRivaroxaban239$166,894
FarxigaDapagliflozin Propanediol53$31,190
JardianceEmpagliflozin42$25,907
EntrestoSacubitril/Valsartan20$10,879
Repatha SyringeEvolocumab13$7,209
Repatha SureclickEvolocumab12$7,029
Metoprolol Succinate424$3,420
Dabigatran EtexilateDabigatran Etexilate Mesylate24$3,379
SotalolSotalol Hcl300$3,282
Diltiazem 24hr Er (Cd)Diltiazem Hcl124$1,673
Amiodarone Hcl224$1,413
Ranolazine ErRanolazine18$986
Flecainide Acetate18$921
Propafenone Hcl28$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$43$267,272404 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,268 family providers in Iowa.

Other family in Sioux City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →